UK cost watchdog turns down Amgen's new cholesterol drug
November 18, 2015 at 08:03 AM EST
LONDON, Nov 18 (Reuters) - Amgen's new injectable cholesterol drug Repatha has been turned down for use on Britain's state health service, underscoring a worldwide debate about the value of such pricey medicines.